Ignite Creation Date:
2025-12-24 @ 11:50 PM
Ignite Modification Date:
2025-12-25 @ 9:44 PM
Study NCT ID:
NCT04416451
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-02
First Post:
2020-06-02
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-04
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06
Completion Date Type:
ESTIMATED
First Submit Date:
2020-06-02
First Submit QC Date:
None
Study First Post Date:
2020-06-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-01
Last Update Post Date:
2025-07-02
Last Update Post Date Type:
ACTUAL